Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX in Korean Adults With Chronic Migraine
NCT02147561Phase 4Completed
- Sponsor
- Allergan
- Start
- Jul 2014
- Primary completion
- Feb 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of onabotulinumtoxinA in chronic migraine, sponsored by Allergan. Primary endpoint: Percentage of Patients With Adverse Events at 28 days. Started Jul 2014; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT02147561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02147561.